Conference Call and Webcast Scheduled for
Wednesday, May 1
SAN
DIEGO, April 10, 2024 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that it has
scheduled its first quarter 2024 financial results conference call
and webcast for 5:00 a.m. Pacific
Time (8:00 a.m. Eastern Time)
on May 1, 2024.
The schedule for the press release and conference call / webcast
is as follows:
|
•
|
Q1 2024 Press
Release:
|
May 1, 2024 at 4:00
a.m. PT / 7:00 a.m. ET
|
|
•
|
Q1 2024 Conference
Call:
|
May 1, 2024 at 5:00
a.m. PT / 8:00 a.m. ET
|
|
•
|
Domestic Dial-In
Number:
|
800-343-4136
|
|
•
|
International Dial-In
Number:
|
203-518-9814
|
|
•
|
Conference
ID:
|
NBIX
|
The webcast can also be accessed on Neurocrine Biosciences'
website under Investors at www.neurocrine.com. A replay of the
webcast will be available on the website approximately one hour
after the conclusion of the event and will be archived for
approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is
a leading neuroscience-focused, biopharmaceutical company with a
simple purpose: to relieve suffering for people with great needs,
but few options. We are dedicated to discovering and developing
life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders. The
company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia, chorea associated with Huntington's disease,
endometriosis* and uterine fibroids*, as well as a robust pipeline
including multiple compounds in mid- to late-phase clinical
development across our core therapeutic areas. For three decades,
we have applied our unique insight into neuroscience and the
interconnections between brain and body systems to treat complex
conditions. We relentlessly pursue medicines to ease the burden of
debilitating diseases and disorders, because you deserve brave
science. For more information, visit neurocrine.com, and
follow the company on LinkedIn, X (Formerly Twitter) and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE
SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
The Neurocrine logo is a trademark of Neurocrine Biosciences,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2024-financial-results-302113406.html
SOURCE Neurocrine Biosciences, Inc.